Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 28Gynecologic 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1CNS 1

Conditions

Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 141Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × dalpiciclib × CNS × Clear all
NCT07539753 2026-04-30

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Nanfang Hospital, Southern Medical University

Phase 2 Not yet recruiting
46 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡